Impact News +++ Corporate News: pferdewetten.de AG (EQS) +++ PFERDEWETTEN.DE Aktie -3,38%

BIOVAXYS Aktie

>BIOVAXYS Performance

1 Woche: 0%

1 Monat: -60,0%

3 Monate: -46,7%

6 Monate: -64,7%

1 Jahr: -67,1%

laufendes Jahr: -64,2%

>BIOVAXYS Aktie

Name:

BIOVAXYS TECHNOLOGY CORP.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA09076M1014 / A2QE16

Symbol/ Ticker:

5LB (Frankfurt)

Kürzel:

FRA:5LB, ETR:5LB, 5LB:GR

Index:

Webseite:

https://biovaxys.com/

Marktkapitalisierung:

6.1 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

-0.009 EUR

Schulden:

0.06 Mio. EUR

Liquide Mittel:

0.14 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

- / 2.18 / -

Gewinnm./ Eigenkapitalr.:

- / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

BIOVAXYS

Letzte Datenerhebung:

25.06.25

>BIOVAXYS Eigentümer

Aktien: 293.42 Mio. St.

f.h. Aktien: 256.21 Mio. St.

Insider Eigner: 5.97%

Instit. Eigner: -

Leerverk. Aktien: -

>BIOVAXYS Peer Group

AVICANNA

CLEARMIND

KNIGHT THERAPEUTICS

MEDICAL FACILITIES

PRINCIPAL TECHNOLOGIES

PROMIS NEUROSCIENCES

THERMA BRIGHT

TILT HOLDINGS

VEXT SCIENCE

VITALHUB

>BIOVAXYS Chart & Kurs - Stuttgart

>BIOVAXYS News

20.06.25 - 08:24	BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered......

04.06.25 - 00:57	BioVaxys Issues Corporate Update (PR Newswire)
	VANCOUVER, BC, June 3, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in February 2024 from the former IMV,......

30.05.25 - 14:03	BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000 (PR Newswire)
	NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, May 30, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces a proposed consolidation of the common shares of the......

30.05.25 - 02:45	BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA") (PR Newswire)
	The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, May 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance......

10.05.25 - 22:12	Sona Nanotech teams with BioVaxys on cancer tech – ICYMI (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

10.05.25 - 04:48	Sona Nanotech teams with BioVaxys on cancer tech – ICYMI (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

09.05.25 - 11:36	Sona Nanotech and BioVaxys Partner to develop next-generation cancer therapies (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 21:24	Sona Nanotech and BioVaxys Partner to develop next-generation cancer therapies (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 15:18	Sona Nanotech Inc.: BioVaxys and Sona Nanotech Enter Research Collaboration (Newsfile)
	Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SO......

23.04.25 - 18:18	BioVaxys und SpayVac-for-Wildlife erweitern Lizenzvereinbarung auf kommerzielle Aquakultur (News Aktuell)
	BioVaxys Technology Corp.: Vancouver, Bc, und Madison, Wisconsin (ots/PRNewswire) - Antragsverfahren zur behördlichen Zulassung von SpayVac für Wildpferde und frei lebende Hirschpopulationen läuft BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ......

22.04.25 - 14:03	BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture (PR Newswire)
	Submission Process Underway for Regulatory Approval of SpayVac in Feral Horses and Free-Ranging Deer Populations VANCOUVER, BC and MADISON, Wis., April 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are......

11.04.25 - 00:37	BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Closing of Debt Settlement Transaction (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, April 10, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce the revocation of the management......

02.04.25 - 00:39	BioVaxys Technology Corp. Announces Debt Settlement Agreement (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, April 1, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has entered into a debt settlement......

18.03.25 - 04:09	BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update (PR Newswire)
	VANCOUVER, BC, March 17, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2025 (the "MCTO"), by its principal regulator,......

04.03.25 - 00:24	BioVaxys Technology Corp. Granted Management Cease Trade Order (PR Newswire)
	VANCOUVER, BC, March 3, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that, further to its news release dated February 13, 2025, its principal regulator, the British Columbia Securities Commission (the "BCSC"), has......

24.01.25 - 02:03	BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Jan. 23, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce, further to its news release of......

17.01.25 - 10:27	BioVaxys entwickelt DPX zum Träger der Wahl für mRNA-Impfstoffe - ein Markt, der bis 2030 auf 48.000.000.000 US-Dollar wachsen soll* (News Aktuell)
	BioVaxys Technology Corp.: Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen") hebt das Potenzial seiner DPX™-Plattform zur nicht-systemischen Immunbildung hervor, die inhärenten Grenzen ......

16.01.25 - 13:01	BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030* (PR Newswire)
	VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for its DPX™ non-systemic immune educating platform to address the inherent limitations of lipid nanoparticles ("LNPs") for......

11.01.25 - 02:30	BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT (PR Newswire)
	// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Jan. 10, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche......

18.12.24 - 15:39	BioVaxys stellt Versorgung mit GMP-konformem Lipid sicher, um DPX-basierte Impfstoffe vor Aufnahme des präklinischen und klinischen Programms herzustellen (News Aktuell)
	BioVaxys Technology Corp.: Vancouver, British Columbia, Kanada (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") hat im Vorfeld der Wiederaufnahme klinischer Studien zu verschiedenen DPX-Formulierungen und ......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram